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A B S T R A C T
Purpose
Despite the generally favorable clinical course in follicular lymphoma (FL), a minority of patients
have a poor prognosis—with death within 3 years of diagnosis—most often due to transformation
to aggressive disease.
Patients and Methods
In this study, we analyzed the potential of predicting early transformation on the basis of gene
expression and immunologic parameters in FL biopsy samples taken at diagnosis.
Results
At the gene-expression level, FL is a highly uniform disease at the time of diagnosis, precluding the
detection of sufficiently validated prognostic gene-expression profiles suitable for a clinical setting.
Combinations of differentially expressed genes indicate that immunologic mechanisms play a
differential role in the risk of early transformation. Using immunohistochemistry for specific cell
populations, the spatial distribution to neoplastic follicles and the activation of CD4–positive
T-helper cells (P  .002) and specifically T-helper 1 (P  .004) were shown to be highly
discriminatory to predict early transformation. A role for functional modulation of follicular dendritic
cells could also be supported (P  .04). Other cell populations, including CD68-positive macro-
phages and regulatory T cells, were not differentially present.
Conclusion
These results support the identification of FL as an immunologically functional disease in which an
interaction of the tumor cells and the functional composition of the microenvironment determines
the clinical behavior.
J Clin Oncol 25:390-398. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma (FL) is the most frequent in-
dolent B-cell lymphoma in adults. Generally, the
disease responds well to chemotherapy, but it is
characterized by frequent relapses. Despite many
different treatment approaches, survival has not im-
proved over the past decades. The disease is still
considered to be incurable. Transformation to ag-
gressive disease in the form of diffuse large B-cell
lymphoma (DLBCL) or to a lesser extent the devel-
opment of nonresponsiveness to therapy without
transformation form the major causes of disease-
related death.1,2
Although a long, indolent course of the dis-
ease is considered to be prototypical, the variation
in survival is quite broad with up to 15% of the
patients dying early in the course of their disease.
A combined score of clinical parameters, such as
the Follicular Lymphoma International Prognos-
tic Index, is considered the most successful prog-
nosticator thus far, but does not reveal any
biologic mechanisms that play a role in transfor-
mation and prognosis.3 Furthermore, to date very
few biologic prognosticators with clinical utility
have been identified. Histologic grading does cor-
relate with clinical outcome both for disease-free
and overall survival.4 Its usefulness for individual
patient management is hampered, however, by its
subjective nature and poor reproducibility.5Most
consistently, a complex karyotype is indicative of
an adverse prognosis.6,7 This is in line with the
current model of transformation being the result
of an accumulation of genetic alterations and pos-
sibly an inadequate repair process.8
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Previous immunohistochemical studies, and more recently
gene-expressionstudies,have lent support toamodelofFLasadisease
of immunologically functional cells in which an interaction of the
tumor cells and the microenvironment determines the clinical
behavior.9-13 It has been hypothesized that the specific genomic alter-
ations in FL cells may actually dictate the functional composition of
the microenvironment.8 The cellular composition of the nonmalig-
nant infiltrate that is related to prognosis and the mechanisms that
play a role are not elucidated yet.
In this study, we explored models on pathogenesis in FL using
gene-expression profiling and immunohistochemistry concentrating
on the risk of transformation as an objective and disease-related bio-
logic end point.
PATIENTS AND METHODS
Patients
From the files of the departments of pathology of the contributing
institutions, three series of samples from patients with FL were collected for
gene-expression studies: representative frozen tissue of biopsy samples of 31
patients who showed histologically or cytologically proven transformation to
DLBCL within 3 years after diagnosis; representative frozen tissue of samples
of 35 patients with fully documented minimum follow-up of 7 years and
without clinical, histologic, or cytologic signsof transformation; and represen-
tative frozen tissue of biopsy samples of 24 patients with DLBCL as transfor-
mation of previously diagnosed FL.
Biopsy samples of FL were included when taken before treatment or
during follow-up after a varying time of watch and wait. Samples were in-
cluded aswell at timeof relapse if biopsy sitewas outside the field of radiother-
apyafter local radiotherapyas initial treatment.Timeofdiagnosis ranged from
1986 to 2004 and treatment protocols were various, including chlorambucil,
combination chemotherapy (cyclophosphamide, vincristin, prednisone), and
radiation therapy. Patients with FL treated with high-dose chemotherapy and
autologous peripheral stem-cell or bone marrow transplantation outside the
context of transformed disease were excluded from the study. None of the
patients received rituximab.
For immunohistochemical analysis, representative formalin-fixed and
paraffin-embedded biopsy samples from 25 patients with transformation
within 3 years using the same selection criteria as discussed earlier were col-
lected. Of these, 15 were also included in the gene-expression study. Thirty-
three instances of patientswithout signs of transformationduring aminimum
follow-up time of 7 years (as described) were included, 15 of which were also
included in the gene-expression analysis. Clinical characteristics of all patients
are listed in Table 1.
Gene-Expression Analysis
RNA isolation, amplification, labeling, and hybridization were per-
formed as previously described.9 Detailed protocols can be found on the
NKI/AvLDepartment of PathologyMicroarray ProjectsWebpage.14 All sam-
pleswerecohybridizedwitha standardreferenceofpooledandamplifiedRNA
isolated from five routine tonsillectomy specimens, chosen and opti-
mized to identify small changes in expression levels between the tumor
groups of interest.
cDNAmicroarray slides, with a complexity of 19,200 spots per slide, were
prepared at theCentralMicroarrayFacility at theNetherlandsCancer Institute. 15
The description of this study follows theminimum information about a
microarray experiment (MIAMI) guidelines issued by the Microarray Gene
Expression Data group.16
Immunohistochemistry
Immunohistochemical stainings were performed on complete paraffin
sections of FL samples according to standard antigenmicrowave/citrate-based
retrieval techniques. Antibodies used are listed in Table 2.
For CD20, the pattern of interfollicular tumor cell distribution was
scored.MIB1 staining was assessed semiquantitatively as a proportion of total
numberof tumorcells.T-cell subpopulationswere semiquantitativelyassessed
in a four-tiered fashion (0% to 1%; 1% to 5%; 5% to 10%; 10%) relative to
total numbers of T-cells and spatial distribution was scored as predominantly
intrafollicular, predominantly interfollicular, or diffuse. CD69 as amarker for
T-cell activation was scored relative to the total number of T cells based on
pattern recognition of the infiltrate. CD69 positivity on tumor cells was not
taken into account. CD21 andCD23 asmarkers for follicular dendriticmesh-
works were scored in a four-tiered system (absent, minority of the neoplastic
follicles with disrupted meshworks, majority of neoplastic follicles with well-
developed meshworks, uniformly well-developed meshworks). CD68-
positive macrophages were counted as absolute cell numbers per three
representative follicular high-power fields (at magnification600). All scor-
ings were performed in a blinded fashion for clinical outcome.
Statistical Analysis
Both for the gene-expression study and the immunohistochemical anal-
ysis, we chose to compare the instances of clinical spectrum extremes, rather
than random samples of FL reflecting an unbiased clinical distribution.9,17
Because the far majority of FL has a favorable prognosis and only approxi-
mately 20% of the patients showed early transformation and/or a poor prog-
nosis, an unbiased series would show a significant under-representation of
poor prognosis patients. This would potentially inhibit the recognition of
minor but biologically significant information in this group. The presently
used choice, however, precludes formal survival and Cox regression analysis.
As a consequence of the protracted clinical course in the majority of the
patients and the dominant elderly age group, patients often die of other causes
than of lymphoma. Therefore, we concentrated on disease-related survival
rather than overall survival.
Unsupervised Analysis
Unsupervised analysis was performed on a selection of the total patient
series consisting of 24 patients with early proven transformation; 22 patients
without transformation; and 24 patients with DLBCL as transformation of
previously diagnosed FL.
Gene clustering was performed on 9,441 significantly differentially
expressed genes, based on the Rosetta error model.18 Agglomerative hier-
archical clustering was performed using complete linkage similarity met-
rics in Genesis.19
Supervisedanalysisof theFLgene-expressiondatawasapproachedusing
several computational strategies based on the Shrunken Centroidsmethod
in the significance analysis ofmicroarrays (SAM) software on a selection of
24 patients with rapid transformation to DLBCL and 22 patients without
transformation20 and on signal-to-noise ratios on a similar selection of
patients groups.
For construction of a formal predictive gene-expression profile, genes
that optimally separated the two classes best were determined by using
different classifier methods in a train and validation protocol as described
by Wessels et al.21,22
RESULTS
Unsupervised Analysis Can Distinguish FL
From DLBCL
As a first step, unsupervised two-dimensional hierarchical clus-
teringwas performedon46FL samples including both clinical groups
and 24 DLBCL samples. This showed a clear separation between FL
andDLBCL, with one cluster containing 75% of DLBCL samples (18
of 24) and only 7% of FL samples (three of 45; Fig 1). Unsupervised
clustering was not able to distinguish clinically favorable FL (n 22)
andunfavorableFL(n24),underlining thebiologichomogeneityof
this disease.
Prognostic Biomarkers in Follicular Lymphoma
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Discriminatively Expressed Genes Between Clinically
Distinct Groups of FL Are Comparable to Genes
Expressed in Activated Lymphoid Tissue
To focus on gene-expression differences between both clinical
groups, reporter genes were selected using SAM as well as signal-
to-noise ratios.
SAM analysis of nontransforming FL (n  22 patients) versus
rapidly transforming FL (n  24) resulted in 86 genes with signifi-
cantly different expression between the two groups (with a false dis-
covery rate of 8%). Signal-to-noise ratios (SNRs) were calculated for a
selection of patients representing the clinical extremes of the spectrum
(Fig. 2).
Gene ontology analysis revealed that both the classical SNR
approach and the SAM approach showed a significant over-
representation between both clinical FL groups of the genes involved
in immunologic functions (30% overall of SAM and SNR identified
genes). Detailed information on these genes and functional grouping
is listed in Table 3. The majority of these immune response–related
geneswere expressed at relatively higher levels in rapidly transforming
FL than in nontransforming FL (25 of 30 markers, excluding the
various immunoglobulins).Moreover, the relative expression levels in
the rapidly transformingFLwere very similar or relatively increased to
normal lymphoid tissuewith follicular hyperplasia, whichwas used as
a hybridization reference, while their expression was relatively down-
regulated innontransformingFL.Therefore, the rapidly transforming
group showed an overall higher similarity of gene expression to follic-
ular hyperplasia.
Table 1. Clinical Characteristics of the Patients in the Gene Expression and Immunohistochemical Studies
Study
FL With Transformation
Within 3 Years
FL Without
Transformation Within
 7 Years P
Transformed FL
(n  24)
Gene Expression
No. of patients 31 35
Interval to transformation
Median 15
Range 3-29 Not applicable 0-169
Follow-up
Median 30 120 57
Range 8-115 89-304 7-180
DOD  DOOC, % 70.9 14.2  .0001 79.1
DOD, % 67.7 8.6  .0001
Age, years .027
Median 52 44 53
Range 30-84 30-76 29-74
Stage III or IV, % 67.7 50 NS
“B” symptoms present, % 29.0 5.9 NS
Poor PS (WHO 2-4), % 0 0 NS
No. extranodal sites  1, % 34.6 6.1 .018
LDH level elevated, % 22.7 0 .032
IPI 0-1 v 2 v 3-5, % 51.7 v 20.7 v 27.5 90.9 v 9.1 v 0
Immunohistochemical
No. of patients 25 33
Interval to transformation, months
Median 14
Range 3-36 Not applicable
Follow-up, months
Median 69 149
Range 7-218 96-276
DOD  DOOC, % 56 24.2 NS
DOD, % 56 16.6 .002
Age, years
Median 55.4 46.2
Range 30-74 30-75 .04
Stage III or IV, % 72 54.5 NS
B symptoms present, % 32 6.2 .04
Poor PS (WHO 2-4), % 0 4.1 .0001
No. extranodal sites  1, % 27.7 4.1 NS
LDH level elevated, % 25 0 .03
IPI 0-1 v 2 v 3-5, % 50 v 27 v 23 97 v 3 v 0
NOTE. An imbalance exists between the two clinical groups of FL known clinical prognostic factors, IPI risk groups, and survival. This is fully in line with rapid and
absent transformation as a selection criterion for the groups and indeed supports that the series is not biased.
Abbreviations: FL, follicular lymphoma; DOD, dead of disease; DOOC, dead of other causes; NS, not significant; PS, performance status; LDH, lactate
dehydrogenase; IPI, International prognostic index.
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Translation of Gene-Expression Patterns to Lymphoid
Cell Populations Using Immunohistochemistry
To further define the cell types involved inprognosis in FL and to
analyze the variations in relative cell numbers and the activation state
of specific cell populations, immunohistochemical studies were per-
formed. The results are summarized in Table 4 and illustrated in
Figure 3. There were no significant differences in tumor cell distribu-
tion and total numbers of T cells. Most importantly, in FL with rapid
transformation, CD4-positive T cells were predominantly found
within the neoplastic follicles with or without an interfollicular com-
ponent. In contrast, the CD4-positive T cells were predominantly
found between the neoplastic follicles in the nontransforming pa-
tients. No differences were found for CD8- andCD57-positive popu-
lations. Virtually no CD56 positive natural killer cells were seen in FL
samples. Specific cell populations of T-helper1 cells and regulatory T
cells were studied using T-bet and forkhead box protein P3 (FOXP3)
immunostainings, respectively. T-helper1 cells were present as a mi-
nor interfollicular population with significantly higher densities in
samples from the rapidly transforming patients, but never exceeding
1% of the total T-cell numbers. Regulatory T cells were present at
varying frequencies in approximately half of the cases containing less
than5%positive cells per total numberofT cells (26of 53).Caseswith
distinctly denser infiltrates of FOXP3-positive cells were not signifi-
cantly different between the two clinical groups.
The activation state of the T cells was significantly higher
(P  .017) in the rapidly transforming patients with uniform
expression of CD69 as an activation marker. In three patients,
tumor B cells uniformly expressed CD69. In all remaining patients,
FL without transformation, minimum follow-up 7 years
FL with transformation within 3 years after diagnosis
DLBCL as transformation of FL
log2 expression ratio
2 -2
Fig 1. Unsupervised two-dimensional hierarchical clustering on 45 follicular lymphoma (FL) samples and 24 diffuse large B-cell lymphomas (DLBCL). FL and DLBCL
can be separated, but not the two clinical categories of FL, patients with transformation within 3 years after diagnosis and those without signs of transformation with
a follow-up of at least 7 years.
Table 2. Antibodies Used in This Study
Antibody Clone Source and Location
Ki-67 MIB1 DAKO, Glostrup, Denmark
CD20 L26 DAKO
CD3 CD3 DAKO
CD4 4B12 Novacastra, Newcastle Upon Tyne, United Kingdom
CD8 C8/144B DAKO
T-bet anti-T-bet Zymed, Invitrogen, Breda, the Netherlands
CD57 leu-7 Becton Dickinson, Franklin Lakes, NJ
CD56 123C3.D5 NeoMarkers
FOXP3 236A/E7 AbCam, Cambridge, United Kingdom
CD21 1F8 DAKO
CD23 1B12 Novacastra
CD68 KP1 DAKO
CD69 CH11 Lab Vision, Fremont, CA
Abbreviation: FOXP3, forkhead box protein P3.
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the architectural pattern of CD69-positive cellsmatched the spatial
distribution of T cells.
CD21 stainings showed that more frequently a disrupted or ab-
sent immunohistochemical pattern in themajority of neoplastic folli-
cles of the rapidly transforming patients (P .04). BecauseCD23was
not differentially expressed, this may reflect a functional modulation
rather than a physical absence of follicular dendritic cells.
CD68-positive cells showed an equal spatial distribution in
both groups. No differences in mean absolute numbers nor in the
proportion of patients with tissue macrophages exceeding the up-
per cutoff level (as described by Farinha et al23) were seen between
the two groups.
Differences in Gene Expression Are Heterogeneous
and Minor, Precluding the Construction of a Reliable
Profile That Can Predict Transformation
To evaluate whether future transformation can be predicted
based on gene expression, 10 different commonly used classification
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Fig 2. Clustering based on 86 genes that were significantly different in gene expression between both clinical groups of follicular lymphoma (FL) according to
significance analysis of microarrays (SAM) analysis is able to separate both groups with a 78% correct stratification. However, because leave-one-out cross validation
and independent validation do not make up part of the SAM analysis, this should not be considered as a predictor profile. DLBCL, large B-cell lymphoma.
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methods were explored as previously published (Wessels et al21). Per-
formance data for each classifier, as well as the median number of
selected genes for the classifier, is given in Table 5 and show that none
of themethods resulted in a validated performance exceeding 55.8%.
Therefore, despite distinct biologic differences at the cell
populations level between both groups, these differences at the
gene-expression level are minor and of a heterogeneous nature,
preventing the construction of a reliable, diagnostic gene-
expression profile that may be useful in clinical practice. Because
the essential biologic differences are found at the level of cell
populations, immunohistochemistry is the more sensitive and in-
formative technique to study this issue rather than gene-expression
profiling. A similar classifying approach was taken to evaluate the
immunohistochemical data (Table 4) andyieldedaclassifier consist-
ing of the four significantly different markers.
DISCUSSION
This gene-expression study shows that FL is at the molecular level a
highly uniform disease at the time of diagnosis. The differences at the
gene-expression level between the extremes of the clinical spectrum
are minor and heterogeneous despite major clinical differences in
terms of risk of transformation and prognosis. These minor differ-
ences at the gene-expression level do contribute to important biologic
insights, however. More than 60% of the most discriminative genes
between FL with documented transformation to DLBCL and FL that
did not transformwithin at least 7 years after diagnosis are involved
in the cellular immune response and inflammatory processes. Glo-
bally, gene-expression patterns in rapidly transforming FL are
more comparable to those in nonmalignant follicular hyperplasia,
Table 3. Differentially Expressed Immune-Related Genes Between Rapidly
Transforming and Nontransforming FL by SAM Analysis and Classical SNR
Related to Functional Cell Populations
Function/Gene
SNR/SAM
Analysis
Expression Nearest to
Reference Follicular
Hyperplasia
Relative Expression
in Rapidly
Transforming FL to
Nontransforming
FL
B-cell differentiation related
genes
PBX1 Both Rapidly transforming FL Increased
Immunoglobulins Both Various Various
CD138 SNR Nontransforming FL Increased
CD9 SNR Rapidly transforming FL Increased
LYN SNR Nontransforming FL Decreased
T-cell subset and function
related genes
CD69 SAM Rapidly transforming FL Increased
Differentiation and
activation
CD101 Both Rapidly transforming FL Increased
MAL2 SNR Rapidly transforming FL Increased
CD2 SAM Nontransforming FL Increased
CXCL1 SAM Rapidly transforming FL Increased
IL-1R Both Rapidly transforming FL Increased
PTPRC SNR Nontransforming FL Decreased
PTPRB SNR Rapidly transforming FL Decreased
PTPRF SNR Rapidly transforming FL Decreased
Natural killer/T function
LIPA SAM Nontransforming FL Increased
TIA1 SAM Nontransforming FL Increased
GZM-K SAM Nontransforming FL Increased
KLRB1 SAM Rapidly transforming FL Increased
SH2D1A SAM Rapidly transforming FL Increased
CXCR6 SAM Nontransforming FL Increased
SLP1 SNR Rapidly transforming FL Increased
TM4SF1 Both Rapidly transforming FL Increased
RAB27B SAM Rapidly transforming FL Increased
T helper1 function
STAT4 SAM Rapidly transforming FL Increased
CCL20 Both Rapidly transforming FL Increased
ELF3 SNR Rapidly transforming FL Increased
IFN- IP16 SNR Nontransforming FL Decreased
IFN-induced TMP3 SNR Rapidly transforming FL Increased
Accessory cell function
CXCL1 Both Rapidly transforming FL Increased
CCL19 SNR Nontransforming FL Increased
CDC42BPK SNR Nontransforming FL Increased
NOTE. Relative gene-expression levels in both clinical groups are compared
with follicular hyperplasia that was used as a reference and the clinical groups
were compared with each other. An overall higher expression of immune-
related genes in the rapidly transforming group and relative similarity or even
increased expression to the expression levels in follicular hyperplasia is seen.
Abbreviations: SAM, significance analysis of microarrays; SNR, signal-to-
noise ratio; FL, follicular lymphoma; IL, interleukin; IFN, interferon.
Table 4. Immunohistochemical Markers in Rapidly Transforming and
Nontransforming FL
Parameter
FL With
Transformation
Within 3 Years
FL Without
Transformation Within
 7 Years P
Grade
3a 1/25 2/33 NS
Ki67
 10% of tumor cells 7/24 4/33 NS
CD20
Interfollicular component 11/24 10/29 NS
CD3
Dense infiltrate 9/25 9/33 NS
CD4
Predominantly intrafollicular 10/24 2/32 .0023
Predominantly interfollicular 3/24 20/32 .0003
CD8
 10% of T cells 11/25 8/33 NS
T-bet
 0.5% of T cells 10/24 1/33 .004
CD57
 10% of T cells 4/16 3/23 NS
FOXP3
 10% of T cells 7/21 4/32 NS
FOXP3
Predominantly interfollicular 10/21 22/32 NS
CD21
Disrupted meshworks 10/25 5/33 0.040
CD23
Disrupted meshworks 7/21 16/32 NS
CD68
Median per 3 HPF 32 34
Range 15-77 19-80 NS†
CD69
 50% of the T cells 18/24 14/33 .017
NOTE. Using the same classifier approaches to construct a formal classifying
profile on the basis of immunohistochemical data as described for the
gene-expression data, all methods yielded a classifier consisting of CD4,
CD21, CD69, and T-bet with significant classification ability (P  .01) and an
accuracy of 61% to 70%.
Abbreviations: FL, follicular lymphoma; NS, not significant; FOXP3, forkhead
box protein P3; HPF, high-power field.
Fisher’s exact test.
†Mann-Whitney U test.
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while nontransforming FL shows overall downregulation of
immune-related genes and therefore may rather resemble nonac-
tivated lymphoid tissue.
Bohen et al12 found similar differences when studying gene-
expression profiles of FL at diagnosis in relation to response to ritux-
imab therapy that was givenmore than 5 years later during the course
of disease. It was shown that nonresponding FL displays a gene-
expression pattern that is more similar to nonmalignant lymphoid
tissue (hyperplastic tonsil).This indicates thatboth rapidly transform-
ingFLand rituximabnonrespondingFLare characterizedbyanactive
immune response. This may be directly involved in the specific bio-
logic characteristics and growth requirements of these FL groups,
possibly as a stimulatory microenvironment.
Dave et al10 described gene-expression patterns in FL in relation
to prognosis, showing a predominance of T-cell-related genes in
good-prognosis FL and expression of accessory cell genes associated
with poor prognosis. At the individual gene level, however, there is
limited overlap with our genes found to be related to transformation
and transformation-related prognosis. Because a custom-made statis-
tical approach with a relative weighing of sets of genes was used by
these authors, complete comparison and cross validationon indepen-
dent series is limited. No obvious separation of transformed versus
A1 B1 C1
A2 B2 C2
D1 E1 F1
D2 E2 F2
Fig 3. Immunohistochemical stainings on full sections of biopsy samples of rapidly transforming follicular lymphoma (FL; panel 1) and nontransforming FL (panel 2)
show different densities and spatial distributions between both clinical groups. (A) CD3; (B) CD8; (C) CD4; (D) CD69; (E) T-bet; (F) CD21.
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nontransforming FL could be achieved using the gene selection as
reported by this group (data not shown). It should be noted that the
patient selection (ends-of-spectrum v continuous spectrum) and end
points (transformation v overall survival) are essentially different be-
tweenDave et al10 andour study, precluding strong conclusions based
on such comparisons.
Combinations of differentially expressed genes identified by this
study point at a role for different T-cell populations, as well as acces-
sory cell populations, such as follicular dendritic cells in FL transfor-
mation. Such differences can be more readily studied at the cellular
level using immunohistochemistry. Using this approach, the activa-
tion of the immune reaction was demonstrated by the observation of
increased expression of the activation marker CD69 on T cells. Few
patients showed uniform expression of CD69 in tumor cells without
clinical correlations. CD4-positive T-helper cells were also shown to
play an important role in rapidly transforming FL. Rather than a
numerical change, differences in spatial distribution and activation of
CD4-positive cellswere seenwithpredominancewithin theneoplastic
follicles. This suggests a functional modulation of this cell population
that may be growth supportive in this group of FL. This notion is
supportedbyboth invitroand invivostudies inmousemodels.24,25As
also suggestedby the combinationof relatively increased expressionof
relatedgenes, an increase in the relative contributionofT-helper1 type
Tcellswasobserved.CD4/CD25 regulatoryTcells, identifiedwith
FOXP3, are specifically involved in suppression of the active immune
response.26-28 In contrast to theprognostic role in solid cancers, itmay
be hypothesized in FL that this cell populationmay rathermediate the
relative immunologically inactive state in good-prognosis FL. How-
ever, neither in terms of absolute cell numbers nor in spatial distribu-
tion (follicular, interfollicular, or diffuse)was our data able to support
this idea.
As also indicated by our gene-expression profiling and analysis,
dendritic cell populations may play a role in the growth properties
and the clinical behavior of FL.29-31Disruptionof theCD21 immuno-
histochemical pattern, in the presence of intact CD23-positive
meshworks within neoplastic follicles, may indicate functional heter-
ogeneity anddifferential interactionswith tumorcells in rapidly trans-
forming FL. In contrast to the findings of others, we were not able to
demonstrate a differential contribution of CD68-positive macro-
phages in relation to the risk of transformation or survival related to
transformation.23 The outline of this study was essentially different
from ours, precluding complete comparison, however. A tissue mi-
croarray (TMA) platform was used, and overall and progression-
free survival were used as end points in contrast to transformation
with essentially different criteria of identifying poor-risk patients.
Moreover, all patients received highly intensified treatment instead
of standard cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) -like therapy.
Our findings further support a hypothetical two-disease model
for FL.8 Such a model may also be supported from a genetic stand-
point. In an elegant study byHöglund et al, 32 the temporal pattern of
the accumulation of genetic alterations in FL was descibed and it was
shown that there may be two mutually exclusive pathways in early
clonal evolution. One pathway is characterized by 6q and 1q as
early changes, in the other pathway by duplication der(18) and7/
8, which can be recognized as relatively early changes. The specific
genetic make-up of the tumor cells may determine the intrinsic sur-
vival capacity and proliferative drive of the tumor cells, as well as the
overall genomic instability. Importantly,molecularlydifferentFLmay
dictate a different microenvironment and by immunologic cross talk
are in a differentmanner influenced byT cells and accessory cells. The
interactingnetworkofgenomicand immunologic factors thendefines
the clinical behavior of the tumor.8
In conclusion, FL has now been recognized as a disease of func-
tionalBcells inwhich the clinical behavior is determinedbyproperties
of the malignant cells in functional cross talk with the immunologic
regulatory network. It will be a challenge over the coming years to
dissect the labyrinth of cellular and molecular information into a
comprehensible and clinically useful model of interactions. Such in-
sights will be of the utmost importance in order to develop intelligent
treatment strategies targeted to specific biologic mechanisms respon-
sible for the ultimately fatal course of the disease.
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Table 5. Validation Performance of Different Predictive
Gene-Expression Profiles
Variable
Mean Validation
Performance (%)
Median No.
of Selected
Genes
Nearest mean 46.5 6
Diagonal linear discriminant 49.4 1
Simple Bayes Gaussian 49.1 36
Nearest neighbor
1 57 259
5 47 101
9 50 11
Regularized fisher linear discriminant
0 55.8 21
1 50.1 281
10 47.7 1
PAM 46 66
Abbreviation: PAM, prediction analysis for microarrays.
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